CA2601400A1 - Improvements in or relating to treatment and prevention of viral infections - Google Patents

Improvements in or relating to treatment and prevention of viral infections Download PDF

Info

Publication number
CA2601400A1
CA2601400A1 CA002601400A CA2601400A CA2601400A1 CA 2601400 A1 CA2601400 A1 CA 2601400A1 CA 002601400 A CA002601400 A CA 002601400A CA 2601400 A CA2601400 A CA 2601400A CA 2601400 A1 CA2601400 A1 CA 2601400A1
Authority
CA
Canada
Prior art keywords
hcv
antibody
group
immunoglobulin
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002601400A
Other languages
English (en)
French (fr)
Inventor
Arvind Patel
Jonathan Ball
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0505697A external-priority patent/GB0505697D0/en
Application filed by Individual filed Critical Individual
Publication of CA2601400A1 publication Critical patent/CA2601400A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002601400A 2005-03-19 2006-03-20 Improvements in or relating to treatment and prevention of viral infections Abandoned CA2601400A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0505697A GB0505697D0 (en) 2005-03-19 2005-03-19 Improvements in or relating to treatment and prevention of viral infection
GB0505697.3 2005-03-19
US31512305A 2005-12-23 2005-12-23
GB0526421A GB0526421D0 (en) 2005-03-19 2005-12-23 Improvements in or relating to treatment and prevention of viral infections
US11/315,123 2005-12-23
GB0526421.3 2005-12-23
PCT/GB2006/000987 WO2006100449A1 (en) 2005-03-19 2006-03-20 Improvements in or relating to treatment and prevention of viral infections

Publications (1)

Publication Number Publication Date
CA2601400A1 true CA2601400A1 (en) 2006-09-28

Family

ID=36754660

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002601400A Abandoned CA2601400A1 (en) 2005-03-19 2006-03-20 Improvements in or relating to treatment and prevention of viral infections

Country Status (6)

Country Link
US (2) US20090110685A1 (enExample)
EP (2) EP2481424A1 (enExample)
JP (1) JP2008532559A (enExample)
AU (1) AU2006226192A1 (enExample)
CA (1) CA2601400A1 (enExample)
WO (1) WO2006100449A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101809033A (zh) * 2007-07-25 2010-08-18 日本国立感染症研究所 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途
CN101939334B (zh) * 2007-12-17 2015-01-14 医疗技术研究局 C型肝炎病毒抗体
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
JP2012512261A (ja) 2008-12-17 2012-05-31 ジェネンテック， インコーポレイテッド Ｃ型肝炎ウイルス併用療法
IN2015DN02826A (enExample) * 2009-09-03 2015-09-11 Merck Sharp & Dohme
CN102596996B (zh) * 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
ITFI20120122A1 (it) 2012-06-15 2013-12-16 Kedrion S P A 50 Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso.
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
RU2539770C1 (ru) 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
BR112016021576A2 (pt) * 2014-03-20 2017-10-10 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases ?anticorpo da proteína e2 de vírus anti-hepatite c ou fragmento do anticorpo que se liga ao antígeno da mesma, ácido nucleico, e, medicamento?
GB201415714D0 (en) 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
US10435463B2 (en) 2014-09-05 2019-10-08 Academisch Medisch Centrum Hepatitis C virus specific antibody
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
JP2022512124A (ja) * 2018-12-06 2022-02-02 シートムエックス セラピューティクス，インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
SU1618761A1 (ru) 1987-04-29 1991-01-07 Институт Белка Ан Ссср Способ получени пептидов и белков в бесклеточной системе трансл ции
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
WO1990005785A1 (en) 1988-11-18 1990-05-31 The Regents Of The University Of California Method for site-specifically incorporating unnatural amino acids into proteins
SU1705302A1 (ru) 1988-12-22 1992-01-15 Институт Белка Ан Ссср Способ препаративной экспрессии генов в бесклеточной системе сопр женной транскрипции/трансл ции
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
WO1991002076A1 (en) 1989-07-31 1991-02-21 Institut Belka Akademii Nauk Sssr Method for obtaining polypeptides in a cell-free system
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5654151A (en) 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002536A1 (en) 1990-08-02 1992-02-20 The Regents Of The University Of Colorado Systematic polypeptide evolution by reverse translation
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DK0562025T3 (da) 1990-12-06 2001-06-18 Affymetrix Inc Forbindelser og deres anvendelse i en binær syntesestrategi
IE914504A1 (en) 1990-12-20 1992-07-01 Ixsys Optimization of binding proteins
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0604552B1 (en) 1991-09-18 1997-02-12 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1995011922A1 (en) 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
ES2276405T3 (es) 1995-06-02 2007-06-16 Gilead Sciences, Inc. Ligandos de oligonucleotidos de alta afinidad a pdgf.
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US5766686A (en) 1996-03-01 1998-06-16 North American Refractories Co. Spray insulating coating for refractory articles
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US5887293A (en) 1998-01-28 1999-03-30 Hennessy; Arnold Simplified dump bucket toilet
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US7201904B2 (en) * 2002-05-16 2007-04-10 The General Hospital Corporation Epitopes of hepatitis C virus
CA2530062A1 (en) * 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
JP2012512261A (ja) * 2008-12-17 2012-05-31 ジェネンテック， インコーポレイテッド Ｃ型肝炎ウイルス併用療法

Also Published As

Publication number Publication date
US20090110685A1 (en) 2009-04-30
AU2006226192A1 (en) 2006-09-28
JP2008532559A (ja) 2008-08-21
EP1863531A1 (en) 2007-12-12
WO2006100449A1 (en) 2006-09-28
EP2481424A1 (en) 2012-08-01
US20140322204A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
US20090110685A1 (en) Treatment and prevention of viral infections
US11535664B2 (en) Multi-valent hepatitis B virus antigen binding molecules and uses thereof
CN108137675B (zh) 中和乙型肝炎病毒的抗体和其用途
Tarr et al. An alpaca nanobody inhibits hepatitis C virus entry and cell‐to‐cell transmission
CA2936877C (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
CN102143975B (zh) 特异性配体在msrv相关疾病中的治疗用途
CN114716541A (zh) 抗冠状病毒的全人广谱中和抗体76e1及其应用
CA2661814A1 (en) Recombinant hcv e2 glycoprotein
KR101450955B1 (ko) Ｈｃｖ 감염의 치료적 처리 및 예방을 위한 의약으로서 항 ｈｃｖ 모노클로날 항체
JP2016504015A (ja) Ｂ型肝炎ウイルスに結合し、かつ中和することができるヒト結合分子およびその使用
JP2004504066A (ja) Ｃ型肝炎ウイルスｅ２糖蛋白質に対するヒトモノクローナル抗体
Cabanillas-Bernal et al. Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2
HK1173979A (en) Improvements in or relating to treatment and prevention of hepatitis c viral infections
AU2012254920A1 (en) Improvements in or relating to treatment and prevention of viral infections
JP2013230152A (ja) ウイルス感染の治療及び予防又は治療及び予防の改善
HK40074417A (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40074418A (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40074418B (en) Antibodies that neutralize hepatitis b virus and uses thereof
CN111153989A (zh) Echo30单克隆抗体的制备及其用途
HK1147501A (en) Antibody having inhibitory activity on infection with hepatitis c virus (hcv), and use thereof
HK1158232B (en) Therapeutic use of specific ligand in msrv associated diseases

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160126